Deutsche Bank AG trimmed its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 70.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 370,002 shares of the biopharmaceutical company’s stock after selling 895,293 shares during the period. Deutsche Bank AG owned about 0.23% of Nektar Therapeutics worth $22,094,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Meeder Asset Management Inc. acquired a new position in shares of Nektar Therapeutics in the 4th quarter valued at approximately $121,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $129,000. Mark Sheptoff Financial Planning LLC raised its position in shares of Nektar Therapeutics by 79.4% during the 3rd quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 2,700 shares in the last quarter. SeaCrest Wealth Management LLC acquired a new stake in shares of Nektar Therapeutics during the 4th quarter valued at approximately $200,000. Finally, Kovack Advisors Inc. acquired a new stake in shares of Nektar Therapeutics during the 4th quarter valued at approximately $240,000. 96.21% of the stock is currently owned by institutional investors.
Several equities research analysts recently issued reports on the company. BidaskClub raised Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Canaccord Genuity reissued a “buy” rating and set a $80.00 price target (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Jefferies Group upped their price target on Nektar Therapeutics to $103.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Cowen reissued a “buy” rating and set a $101.00 price target on shares of Nektar Therapeutics in a research report on Friday, March 2nd. Finally, Mizuho reissued a “buy” rating and set a $89.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, February 14th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $54.75.
Nektar Therapeutics (NASDAQ NKTR) opened at $104.01 on Friday. The company has a market capitalization of $17,250.93, a price-to-earnings ratio of -160.02 and a beta of 1.96. The company has a debt-to-equity ratio of 2.79, a quick ratio of 5.63 and a current ratio of 5.82. Nektar Therapeutics has a 52 week low of $17.33 and a 52 week high of $111.36.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.14. The firm had revenue of $95.47 million during the quarter, compared to the consensus estimate of $36.96 million. Nektar Therapeutics had a negative return on equity of 156.85% and a negative net margin of 31.42%. The firm’s revenue was up 154.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.28) EPS. analysts anticipate that Nektar Therapeutics will post -1.33 earnings per share for the current year.
In related news, COO John Nicholson sold 220,144 shares of the company’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $99.27, for a total transaction of $21,853,694.88. Following the completion of the transaction, the chief operating officer now directly owns 267,657 shares in the company, valued at approximately $26,570,310.39. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Jillian B. Thomsen sold 2,545 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $82.94, for a total value of $211,082.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 399,592 shares of company stock valued at $36,001,781. 5.44% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/23/nektar-therapeutics-nktr-holdings-lessened-by-deutsche-bank-ag.html.
Nektar Therapeutics Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.